ABSTRACT
Importance Smoking is associated with atherosclerotic cardiovascular disease, but the relative contribution to each subtype (coronary artery disease [CAD], peripheral artery disease [PAD], and large-artery stroke) remains less well understood.
Objective To determine the effect of smoking on risk of coronary artery disease, peripheral artery disease, and large-artery stroke.
Design Mendelian randomization study using summary statistics from genome-wide associations of smoking (up to 462,690 individuals), coronary artery disease (up to 60,801 cases, 123,504 controls), peripheral artery disease (up to 24,009 cases, 150,983 controls), and large-artery stroke (up to 4,373 cases, 406,111 controls)
Setting Population-based study of primarily European-ancestry individuals
Participants Participants in genome-wide association studies of smoking, coronary artery disease, peripheral artery disease, and stroke.
Exposures Genetic liability to smoking defined by lifetime smoking index: an integrated measure of smoking status, age at initiation, age at cessation, number of cigarettes smoked per day, and declining effect of smoking on health outcomes).
Main Outcome Measure Risk of coronary artery disease, peripheral artery disease, and large-artery stroke.
Results Genetic liability to smoking was associated with increased risk of PAD (OR 2.13; 95% CI 1.78-2.56; P = 3.6 × 10−16), CAD (OR 1.48; 95% CI 1.25-1.75; P = 4.4 × 10−6), and stroke (OR 1.4; 95% CI 1.02-1.92; P = 0.036). Risk of PAD in smokers was greater than risk of large-artery stroke (pdifference = 0.025) or CAD (pdifference = 0.0041). The effect of smoking on ASCVD remained independent from the effects of smoking on traditional cardiovascular risk factors.
Conclusions and Relevance Genetic liability to smoking is a strong, causal risk factor for CAD, PAD, and stroke, although the effect of smoking is strongest for PAD. The effect of smoking is independent of traditional cardiovascular risk factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is based on data from the MVP, Office of Research and Development, Veterans Health Administration and was supported by award no. MVP000. This work was supported by US Department of Veterans Affairs grants IK2-CX001780 (SMD), and I01-BX003362 (PST). This publication does not represent the views of the Department of Veterans Affairs or the United States government. This work was supported by American Heart Association Strategically Focused Research Network in Vascular Disease grant 18SFRN33960373 (MSF); National Heart, Lung, and Blood Institute grants HL125032 (MSF) and R01HL142711 (PN); National Institute of Diabetes and Digestive and Kidney Diseases DK101478 and HG010067 (BFV); and a Linda Pechenik Montague Investigator Award (BFV).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
